Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00136396 · ClinicalTrials.gov registry record · Phase 1
Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease
A Phase 1 study of Graft Vs Host Disease, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00136396 is a Phase 1 study of Graft Vs Host Disease that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00136396, a Phase 1 study of Graft Vs Host Disease, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine if rituximab is a safe and effective therapy for steroid-refractory chronic graft versus host disease (GVHD).
Conditions Studied
Interventions
- DRUG Rituximab
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-01 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00136396
The ClinicalTrials.gov registry entry for NCT00136396 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 36 other Graft Vs Host Disease trials with a reported enrollment target (78% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Graft Vs Host Disease appearing as the primary indexed condition, and to 1 intervention - of which Rituximab is the first listed.
NCT00136396 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00136396 about?
NCT00136396 is a clinical study titled "Rituximab Therapy for Steroid-Refractory Chronic Graft Versus Host Disease". The purpose of this study is to determine if rituximab is a safe and effective therapy for steroid-refractory chronic graft versus host disease (GVHD).
What is the current status of trial NCT00136396?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2004-01. Estimated completion is 2010-11.
What conditions does trial NCT00136396 study?
This clinical trial studies the following conditions: Graft Vs Host Disease.
What interventions are being tested in trial NCT00136396?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00136396?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00136396 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graft Vs Host Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
IS-free Treg HaploHCT
RECRUITING · Phase 1
-
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Abatacept for the Prevention of Graft-Versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
RECRUITING · Phase 1
-
Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
RECRUITING · Phase 1
-
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
COMPLETED · Phase 1
-
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.